Cargando…
Enhancing the oral bioavailability of biochanin A by encapsulation in mixed micelles containing Pluronic F127 and Plasdone S630
Biochanin A (BCA), a natural dietary isoflavone, has been reported to show anticancer activities. However, its low biological availability and poor aqueous solubility limit its usefulness as a chemotherapeutic agent. We developed BCA-loaded micelles with Pluronic F127 and Plasdone S630 (BCA-FS). The...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328660/ https://www.ncbi.nlm.nih.gov/pubmed/28260893 http://dx.doi.org/10.2147/IJN.S125041 |
_version_ | 1782510918493536256 |
---|---|
author | Wu, Xiaoyan Ge, Weihong Shao, Tengfei Wu, Weijun Hou, Jian Cui, Li Wang, Jing Zhang, Zhenghai |
author_facet | Wu, Xiaoyan Ge, Weihong Shao, Tengfei Wu, Weijun Hou, Jian Cui, Li Wang, Jing Zhang, Zhenghai |
author_sort | Wu, Xiaoyan |
collection | PubMed |
description | Biochanin A (BCA), a natural dietary isoflavone, has been reported to show anticancer activities. However, its low biological availability and poor aqueous solubility limit its usefulness as a chemotherapeutic agent. We developed BCA-loaded micelles with Pluronic F127 and Plasdone S630 (BCA-FS). The optimized, spherical-shaped BCA-FS was obtained at a ratio of 1:1 (F127:S630). The particle size was 25.17±1.2 nm, and the zeta potential was −10.9±0.24 mV. BCA solubility in water increased to 5.0 mg/mL after encapsulation, and the drug-loading efficiency was 5.88%±0.76%. In vitro release experiments showed a delayed release of BCA from the mixed micelles. Furthermore, the BCA absorption permeability across a Caco-2 cell monolayer from the apical side to the basolateral side increased by 54% in BCA-FS. A pharmacokinetics evaluation showed a 2.16-fold increase in the relative oral bioavailability of BCA-FS compared with raw BCA, indicating that the mixed micelles may promote absorption in the gastrointestinal tract. A gastrointestinal safety assay was used to assess the reliability and safety of BCA-FS. On the basis of these findings, we conclude that this simple nanomicelle system could be leveraged to deliver BCA and other hydrophobic drugs. |
format | Online Article Text |
id | pubmed-5328660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53286602017-03-03 Enhancing the oral bioavailability of biochanin A by encapsulation in mixed micelles containing Pluronic F127 and Plasdone S630 Wu, Xiaoyan Ge, Weihong Shao, Tengfei Wu, Weijun Hou, Jian Cui, Li Wang, Jing Zhang, Zhenghai Int J Nanomedicine Original Research Biochanin A (BCA), a natural dietary isoflavone, has been reported to show anticancer activities. However, its low biological availability and poor aqueous solubility limit its usefulness as a chemotherapeutic agent. We developed BCA-loaded micelles with Pluronic F127 and Plasdone S630 (BCA-FS). The optimized, spherical-shaped BCA-FS was obtained at a ratio of 1:1 (F127:S630). The particle size was 25.17±1.2 nm, and the zeta potential was −10.9±0.24 mV. BCA solubility in water increased to 5.0 mg/mL after encapsulation, and the drug-loading efficiency was 5.88%±0.76%. In vitro release experiments showed a delayed release of BCA from the mixed micelles. Furthermore, the BCA absorption permeability across a Caco-2 cell monolayer from the apical side to the basolateral side increased by 54% in BCA-FS. A pharmacokinetics evaluation showed a 2.16-fold increase in the relative oral bioavailability of BCA-FS compared with raw BCA, indicating that the mixed micelles may promote absorption in the gastrointestinal tract. A gastrointestinal safety assay was used to assess the reliability and safety of BCA-FS. On the basis of these findings, we conclude that this simple nanomicelle system could be leveraged to deliver BCA and other hydrophobic drugs. Dove Medical Press 2017-02-22 /pmc/articles/PMC5328660/ /pubmed/28260893 http://dx.doi.org/10.2147/IJN.S125041 Text en © 2017 Wu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Wu, Xiaoyan Ge, Weihong Shao, Tengfei Wu, Weijun Hou, Jian Cui, Li Wang, Jing Zhang, Zhenghai Enhancing the oral bioavailability of biochanin A by encapsulation in mixed micelles containing Pluronic F127 and Plasdone S630 |
title | Enhancing the oral bioavailability of biochanin A by encapsulation in mixed micelles containing Pluronic F127 and Plasdone S630 |
title_full | Enhancing the oral bioavailability of biochanin A by encapsulation in mixed micelles containing Pluronic F127 and Plasdone S630 |
title_fullStr | Enhancing the oral bioavailability of biochanin A by encapsulation in mixed micelles containing Pluronic F127 and Plasdone S630 |
title_full_unstemmed | Enhancing the oral bioavailability of biochanin A by encapsulation in mixed micelles containing Pluronic F127 and Plasdone S630 |
title_short | Enhancing the oral bioavailability of biochanin A by encapsulation in mixed micelles containing Pluronic F127 and Plasdone S630 |
title_sort | enhancing the oral bioavailability of biochanin a by encapsulation in mixed micelles containing pluronic f127 and plasdone s630 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328660/ https://www.ncbi.nlm.nih.gov/pubmed/28260893 http://dx.doi.org/10.2147/IJN.S125041 |
work_keys_str_mv | AT wuxiaoyan enhancingtheoralbioavailabilityofbiochaninabyencapsulationinmixedmicellescontainingpluronicf127andplasdones630 AT geweihong enhancingtheoralbioavailabilityofbiochaninabyencapsulationinmixedmicellescontainingpluronicf127andplasdones630 AT shaotengfei enhancingtheoralbioavailabilityofbiochaninabyencapsulationinmixedmicellescontainingpluronicf127andplasdones630 AT wuweijun enhancingtheoralbioavailabilityofbiochaninabyencapsulationinmixedmicellescontainingpluronicf127andplasdones630 AT houjian enhancingtheoralbioavailabilityofbiochaninabyencapsulationinmixedmicellescontainingpluronicf127andplasdones630 AT cuili enhancingtheoralbioavailabilityofbiochaninabyencapsulationinmixedmicellescontainingpluronicf127andplasdones630 AT wangjing enhancingtheoralbioavailabilityofbiochaninabyencapsulationinmixedmicellescontainingpluronicf127andplasdones630 AT zhangzhenghai enhancingtheoralbioavailabilityofbiochaninabyencapsulationinmixedmicellescontainingpluronicf127andplasdones630 |